Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile New antibody-drug conjugate (ADC) candidate, ZW327, ...
Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile New antibody-drug conjugate (ADC) candidate, ZW327 ...
Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half ...
The clinical candidate you might most associate with TIL's ticker is CoStAR-TIL, which takes a patient's tumor-infiltrating lymphocytes and engineers them to express a CD28/CD40 chimeric ...
Building upon ARC101 as a foundation, Third Arc Bio continues to invest in its Synergy Platform to develop a pipeline of novel CD3 and CD28 targeting multispecifics to create transformational drugs ...
HOUSE, PA — Third Arc Bio Inc. has administered the first dose of ARC101 to a patient in its inaugural first-in-human ...
Findings showed that HLA DR expression on B cells and the absolute number of CD28–CD4–CD8—T cells were associated with a protective effect against AD, while 13 other immunological phenotypes were risk ...
Indiana basketball's Mike Woodson coached his last game at Simon Skjodt Assembly Hall on Saturday. In a postgame interview with CBS after IU's 66-60 win over Ohio State, Woodson said "he couldn't ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback